Catalyst
Slingshot members are tracking this event:
AveXis' (AXVS) AVXS-101 in Treatment of Spinal Muscle Atrophy (SMA) Granted Priority Medicines (PRIME) Program by the European Medicines Agency
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AVXS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 06, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Avxs-101, Spinal Muscle Atrophy, Sma, Priority Medicines Program, Prime, European Medicines Agency
